Senseonics Holdings, Inc. Common Stock

The global blood glucose monitoring system market is valued at USD 16.8 billion in 2025 and is projected to reach USD 39.4 billion by 2035, growing at a CAGR of 8.9%. Growth is driven by AI-enabled monitoring systems, increasing diabetes prevalence, and rising adoption of home healthcare solutions. Key players include Medtronic, Abbott, Dexcom, a...

Senseonics Holdings announced a $80 million underwritten public offering of 8 million shares at $5.00 per share and pre-funded warrants. The offering is expected to close on May 4, 2026. Net proceeds will fund the launch of Eversense 365 and development of pipeline products.

The Middle East and Africa CGM market is projected to grow from USD 320.44 million in 2025 to USD 855.30 million by 2034 at an 11.53% CAGR, driven by rising diabetes prevalence, healthcare infrastructure improvements, and digital health integration. Key growth factors include government initiatives promoting preventive care and increasing smartph...

Senseonics launched its Eversense 365 continuous glucose monitoring system in Sweden with planned rollouts in Germany, Spain, and Italy. The implantable CGM doubles sensor lifespan to one year compared to its predecessor and reduces calibration frequency from daily to weekly. The company reported Q4 2025 revenue of $14.3 million, a 72% year-over-...

The healthcare sector is shifting toward outpatient clinics and ambulatory services, with AI-powered diagnostics and remote care technologies gaining significant traction. Multiple medtech companies are advancing innovative solutions: VentriPoint Diagnostics is expanding cardiac imaging to remote communities via partnership with First Light Healt...